{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:13Z","timestamp":1791414133259,"version":"4.3.3"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activity of solithromycin was evaluated against clinical\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Legionella pneumophila<\/jats:named-content>\n            serogroup 1 (Lp1) isolates (\n            <jats:italic>n<\/jats:italic>\n            = 196) collected in Ontario, Canada, from 1980 to 2011. Its\n            <jats:italic>in vitro<\/jats:italic>\n            activity was compared to that of azithromycin (AZM) using the broth microdilution method. Solithromycin had a MIC\n            <jats:sub>50<\/jats:sub>\n            of \u22640.015 \u03bcg\/ml and a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.031 \u03bcg\/ml, making its activity at least 8-fold to 32-fold higher than that of AZM (MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.125 \u03bcg\/ml and 1 \u03bcg\/ml, respectively). Ninety-nine percent of the isolates had MICs for solithromycin ranging from \u22640.015 \u03bcg\/ml to 0.031 \u03bcg\/ml, whereas 83.6% of the isolates showed MICs for AZM ranging from 0.062 \u03bcg\/ml to 0.25 \u03bcg\/ml. Interestingly, 96.7% (30 out of 31 clinical isolates) identified with higher AZM MICs (0.5 \u03bcg\/ml to 2 \u03bcg\/ml) belonged to the clinically prevalent sequence type 1. To investigate the intracellular activity of solithromycin,\n            <jats:italic>in vitro<\/jats:italic>\n            invasion assays were also performed against a subset of representative Lp1 isolates internalized within human lung epithelial cells. Solithromycin and AZM both inhibited growth of all intracellular Lp1 isolates at 1\u00d7 or 8\u00d7 MICs, displaying bacteriostatic effects, as would be expected with protein synthesis inhibitor rather than bactericidal activity. Solithromycin demonstrated the highest\n            <jats:italic>in vitro<\/jats:italic>\n            and intracellular potency against all Lp1 isolates compared to AZM. Given the rapid spread of resistance mechanisms among respiratory pathogens and the reported treatment failures in legionellosis, the development of this new fluoroketolide, already in phase 3 oral clinical studies, constitutes a promising alternative option for the treatment of legionellosis.\n          <\/jats:p>","DOI":"10.1128\/aac.01639-13","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T03:28:07Z","timestamp":1385436487000},"page":"909-915","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Antimicrobial Activity of Solithromycin against Clinical Isolates of Legionella pneumophila Serogroup 1"],"prefix":"10.1128","volume":"58","author":[{"given":"Julia","family":"Mallegol","sequence":"first","affiliation":[{"name":"Public Health Ontario Laboratory, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cempra Inc., Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto G.","family":"Melano","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Guyard","sequence":"additional","affiliation":[{"name":"Public Health Ontario Laboratory, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550170034023"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/342903"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2006.18.5.559"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.3.506-526.2002"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/aem.41.1.9-16.1981"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/341087"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.72.2.1613-1622.2006"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/es034368i"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1120800"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2012.07.005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg054"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00095-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.6.815"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.001"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.01.026"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01662-09"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-10"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00197-13"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1603.081689"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-7-102"},{"key":"e_1_3_3_22_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07-A8","author":"CLSI","year":"2009","unstructured":"CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.08.019"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.12.015"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00788-10"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1777-1783.2003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099776"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.11.2701-2705.1987"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.3.1401"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.3.518"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-10"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00564-13"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.09.016"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.7229808"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06180-11"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1367"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3020-3025.2002"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2503-2506.2000"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.08.005"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.2.289"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00203-09"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01639-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01639-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:37:26Z","timestamp":1645483046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01639-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/AAC.01639-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01639-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"2013-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}